中西医结合治疗乙型肝炎肝纤维化31例

Therapy of Integrated Medicine in the Treatment of Hepatic Fibrosis for 31 Cases

目的探究中西医结合治疗方法在乙型肝炎肝纤维化患者的临床治疗过程中的治疗效果。方法随机选取2014年1月—2016年2月就诊并治疗的62例慢性乙型肝炎患者。将其平均分为观察组与对照组2组,每组31例患者。观察组患者给予中西医联合治疗方式治疗,对照组患者给予单纯的西医治疗方式治疗。观察并对比两组患者接受治疗12周前后肝功能指标如血清谷丙转氨酶(ALT)、谷草转氨酶(AST)水平及肝纤维化指标如透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)、Ⅳ型前胶原(PC-Ⅳ)的改变情况。结果 2组患者接受治疗12周后ALT、AST指标及HA、PC-Ⅲ、PC-Ⅳ指标均较治疗前有所改善,但观察组患者明显优于对照组患者,并且差异具有统计学意义(P<0.05)。结论中西医联合方式对于治疗乙型肝炎患者肝纤维化效果更佳,值得在临床上被考虑并推广使用。

Objective To explore the therapeutic effect of therapy of integrated medicine in the treatment of hepatitis B patients with liver fibrosis. Methods 62 cases of patients with chronic hepatitis B were randomly selected in our hospital. They were divided into the observation group and the control group, with 31 cases in each group. The observation group was treated with combination of tra-ditional Chinese and Western medicine treatment, and the control group was treated with simple Western medicine treatment. The liv-er function indexes before and after 12 weeks such as serum alanine aminotransferase（ALT）, aspartate aminotransferase（ AST）level and liver fibrosis indexes such as transparent hyaluronic acid（HA）, laminin laminin）, type III procollagen（PC III）, type IV collagen IV（PC） changes were observed and compared. Results ALT and AST, ha, PC III, PC IV index of two groups received treatment of 12 weeks improved than those before treatment, and the observation group was significantly better than the control group,and the difference were statistical significant（ P〈0.05）. Conclusion The therapy of integrated medicine in the treatment of hep-atitis B with liver fibrosis is better, and it is worth to be considered in clinical practice.